PD G RIFFITHS . Cytomegalovirus and human herpesviruses 6 and 7 : Diseases and diagnosis in transplantation. Can J Infect Dis 1993;4(Suppl C):26C-32C. Similarities and differences in the epidemiology of cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and human herpesvirus 7 (JIIN-7) infections are reviewed. Several distinct laboratory methods have been described for each virus. For CMV in immunocompromised patients, infection is best diagnosed by identifying active infection using routine surveillance cu ltures. Patients with active infection can then be entered into trials of suppressive therapy (where virus excretion is from the urine or saliva) or pre-emptive therapy (where excretion is detected systemically). For HHV-6 and Hf-N-7, only anecdotal cases of associations with disease in immunocomprom ised patients have been reported. Recommendations cannot therefore be made about appropriate diagnostic strategies or about treatment since it is not clear if these viruses are pathogens or passengers.
H ERPESVIRUSES ARE CLASSICAL OPPORTUNISTS IN TIIAT
they reactivate when a patient is otherwise debilitated. It follows that herpesviruses can regularly be found in a variety of medical conditions which are immunocompromising or which require immunosuppressive drugs for their treatment. However. the mere presence of a herpesvirus in a patient does not necessa.Jily mean that. disease will result, and criteria which should be satisfied before a herpesvirus is associated with a particula.~· disease have been reviewed. This paper summarizes how and why infections with two herpesviruses should be sought in transplant patients.
CYTOMEGALOVIRUS
As reviewed elsewhere in this issue, it is clear that cytomegalovirus (CMV) is the cause of several distinct clinical syndromes. Over the past decade, several research groups have contributed to the knowledge about. the natural history of CMV infections in transplant. patients. This information is an essential prelude to the design and conduct of controlled tiials designed to interfere with natural history. Given this framework, the objectives of the laboratory are to guide clinical colleagues on potential management changes for individual patients under their care ( Table 1) . Each of these laboratory objectives will be considered in turn. Pretransplant assessment: CMV antibodies of immunoglobulin (lg) G class should be sought using one of a range of sensitive methods which are widely available. The presence of IgG a.Jltibodies in donors indicate that. they a.~·e at risk of !J·ansmilting virus to the recipient. (l) . The presence of a.Jltibody in a recipient indicates that. the patient is at. risk of reactivating virus after transplantation (2). In the case of herpes simplex, the height of the pret.ranspla.Jlt IgG level is generally predictive of future reactivation (3). but this is not true for CMV (4). Post-transplant assessment: Once the patient is receiving immunosuppressive drugs, ability to mount a humoral immune response should not. be relied upon for diagnostic purposes. Several methods exist for the detection of CMV. Cell culture remains the gold standard against which all newer methods must be compared. Nearly a decade ago. monoclonal antibodies reactive with the major immediate-early proteins of CMV were used in culture conformation to significantly shorten the lime required for detection of CMV. This approach is termed DEAFF (detection of early antigen fluorescent foci) or shell vial technique (5,6). The sensitivity is lower than that of cell culture but can be significa.Jllly increased by centrifugation of clinical san1ple and cell culture before incubation. Monoclonal antibodies have also been used to detect CMV-specific antigens in leukocytes (polymorphonuclear and monocytes) from cytospin preparation of peripheral blood (7-9). Monoclonal antibodies used for this technique do not react with immediate-early antigens as originally thought., but recognize an early phosphoprotein of molecular weight ratio 65 termed the lower matrix protein (10). Finally. several meU1ods for the detection of CMV by polymerase chain reaction (PCR) have been described (11 -13).
The diagnosis of CMV infection after transplantation should ideally be made by collection of regular surveillance samples taken from lime of transplant onwards. Most laboratories collect weekly urine. saliva and blood for this purpose and process U1em by one or more of the meU1ods described above. Wherever possible. samples from a diseased organ such as liver biopsy or bronchoalveolar lavage should be collected to provide evidence of tissue infection. CMV disease should be classified according to a clinical scoring scheme ( Table 3 shows the use of this approach for three distinct groups of transplant. patients under the care of clinical colleagues at the Royal Free Hospital School of Medicine. Samples from all patients were processed by cell culture and DEAFF. CMV infection is very common in transplant patients, but CMV disease does not occur in the same proportion of subgroups of patients. For example. in renal allograft patients. disease is largely restricted to those experiencing p1imary infection or reinfection from the donor organ (16). In contrast, bone marrow transplant patients have the most severe disease if their own virus is reactivated after transplantation (2). In our series. but not in others, a reduced incidence of disease was found if the marrow donor was seropositive (17) . This may be due to the use ofT cell depletion. which may remove the cell s harbouring CMV infection, as well as those mediating graft-versus-host. disease after transplantation. Under these circumstances, residual immunity in the donor may be adoptively transferred into the recipient. (18) . Since the donor marrow has been depleted of mature T cells. this suggests U1at the protective mechanism is non-T in origin, presumably B cell-mediated. The possibility of adoptive transfer of humoral immunity has been investigated by immunizing donors immediately before transplantation; the best results were obtained when the recipient as well as the donor were immunized (19).
The results from surveillance cultures can be analyzed in a different way to determine how much prognostic information they produce for the average patient. Under these circumstances, the detection of CMV is assumed to be clinically useful only if it occurs in samples taken before the onset of disease in the patient. This a pproach was pioneered by the Seattle group , which showed an overall sensitivity of 69%, with a positive predictive valu e for CMV viremia of 60% using blood cultures maintained for five weeks (20). In an attempt to make prognostic information more readily available to physicians, we h ave used the DEAFF test, and found a lower sensitivity of about 50% but a positive predictive valu e of 64% (21). In renal transplant patients, we found a sensitivity of 79% and a positive predictive value of viremia of 46% (22). with a similar trend for liver transplant patients (23). Clearly, these results indicate that the sensitivity of surveillance cultures needs to be improved, but that viremia provides good prognostic value when it is detected. These results s hould therefore support the more widespread introduction of pre-emptive therapy where asymptomatic patients with CMV viremia are treated with an antiviral drug s u ch as ganciclovir (24) . In addition, the study s hould prompt more widespread evaluation of 'suppression', defined as administration of an antiviral drug 28C Y ·DO NOT COPY to patients excreting only from peripheral sites of urine and/or saliva (25). Finally, these results should also stimulate U1e conduct of formal prognostic studies for newer meU1ods such as polymerase chain reaction (PCR), which offer greatly increased sensitivity. Such studies must be conducted at each laboratory as van-· ations in cell culture lines, techniques used, lengths of incubation, and anticoagulants used, can significantly alter the performance of a particular assay and the cell culture result with which it must be compared. Viremia should, therefore, not be seen as an all or none phenomenon but as a continuum which will be detected more readily by the most sensitive assays , but which will not necessarily be associated with severe disease in all cases. The ability to quantify PCR reactions should facilitate a greater refinement of the prognostic value of these assays (26). Detection of resistant strains: Soon after ganciclovir became widely available for U1e treatment of CMV infections, strains of virus with reduced in vitro sensitivity to the drug were reported. For example, Erice et al (27) showed that strains of virus could acquire resistance to ganciclovir or could be selected during the course of an infection in vivo. The precise pathological potential of such resistant strains must be determined, but it seems likely that alternative therapy will be required for at least some patients, as has been described for herpes simplex (28) . One resistant strain has been studied in detail using marker rescue techniques, and resistance has been shown to map to two distinct genes: DNA polymerase and the product of the UL97 gene (29, 30) . By analogy with herpes simplex. the DNA polymerase mutant presumably has a reduced ability to recognize ganciclovir triphosphate. However, the UL97 gene provides a novel molecular target for CMV chemotherapy. The gene has been shown to code for a protein with a relative molecular mass of approximately 80,000, which is homologous USE to protein kinases. A truncated protein with a relative molecular mass of approximately 39.000 was expressed in Escherichia coli and contained all of the predicted catalytic domains of the protein kinases. Extracts from the E coli were shown to phosphorylate ganciclovir and an antiserum reactive against UL97 was shown to neutralize the kinase activity.
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An alternative drug for treating resistant strains is foscarnel. CMV strains resistant to ganciclovir are reported to be sensitive to this drug. In addition. the two drugs exhibit synergistic activity in vitro. They have been given together in patients, but there is at least one report of a strain of CMV resistant to both agents (31).
HUMAN HERPESVIRUSES 6 AND 7
Human herpesviruses 6 (HHV -6) and 7 (HHV-7) were not identified until 1986 and 1990, respectively, so much less information is available about their natural history than is the case for the other herpesviruses (32, 33) . Nevertheless, it appears that infection with both is commonly acquired in early childhood and that both viruses are frequently excreted in saliva (34) (35) (36) (37) . This is supported by the results of in situ hybridization and immunocytochemistry of salivary glands (38) . One report describes the isolation of HHV -7 only from the saliva of adults, although this virus activated HHV-6 from the donor lymphocytes used for culture which became dominant subsequently (39) . Most infected individuals exhibit no symptoms, suggesting that the natural history of these viruses resembles that of CMV or Epstein -Barr virus (EBV) rather than varicella-zoster virus (VZV). Molecular analyses of the genome ofHHV-6 suggest that it is genetically related to CMV, with conserved blocks of genes colinear with their CMV counterparts (40) . A map of restriction enzyme sites has been published (41) .
HHV -6 has been shown to be the cause of exanthema subitum, a mild. self-limiting common childhood illness (42) . Exanthema subitum was shown in 1950 to be transmissible to a six-month-old child and to macaques (43) . In addition, case reports have associated HHV-6 with a variety of conditions. These are ranked in Table 4 , from those which are probably caused by the virus to those which are purely speculative. This speculation includes the suggestion that HHV-6 could act as a cofactor to increase the rate at which acquired immunodeficiency syndrome (AIDS) develops following infection with human immunodeficiency virus (HIV). This is based upon in vitro experiments which show that HHV-6 can increase HN replication in co-infected cells by stimulating transcriptional factors (44) . or by transactivation (45.46) , although this activation is dependent upon the reporter gene used (47) . HHV-6 can up-regulate the CD4 molecule in CDS cells to render them susceptible to HN infection (48) . However, another report shows that HHV-6 inhibits HN replication in cell culture (49 84 that HHV-6 adversely affects progression of HN infection (50) . although anoll1er does (51) .
At present, there are no diseases associated with HHV-7 infection. Seroconversion to I-IHV-7 in a small number of heallliy children appears to occur from the second year of life onwards (39) . Diagnosis of infection: Virus isolation has so far been the mainstay of diagnosis of this new herpesvirus (52, 53) . Immediate-early antigens have been idenWied and could be used for rapid viral diagnosis (54) . Several PCR methods have been described (36, (55) (56) (57) . 11. is hoped that they, in conjunction wiU1 virus isolation. will be evaluated critically, as was described earlier for CMV, to help determine the lrue clinical significance of this virus (58) .
In addition, some authors have begun to type strains of virus using slot-blot. restriction enzyme analysis, or PCR with sequencing of amplimers (59) . Whether the strains associated with exanl11ema subitum should be differentiated taxonomically fron1 U1e remaining strains is controversial (60) .
The first serological tests used immunofluorescence. either using antihuman conjugates or using anticomplement immunofluorescence (61, 62) . Given the genetic relationship with CMV, the fact that the virus may activate host cell proteins (63) and U1e possibility lliat it may encode an Fe receptor, it has been difficult for investigators to determine uniequivocally a true cut-off between seropositive and seronegative. When serum dilutions of 1:80 are used in indirect immunofluorescence. then, typically, 80% of the population are shown to be seropositive. Serological responses in patients have been reported during CMV infections. and vice versa. Whether this results from antigenic cross-reaction or co-reactivation of both herpesviruses in immunocompromized patients. is unknown (64) (65) (66) . Other serological methods have been described, including enzyme immunoassay (67, 68) , lgM detennination (69.70). Western blotting (51) and radioimmunoprecipitation (71) . but their specificity and sensitivity remain to be determined. 
